Navigation Links
SemBioSys begins phase I/II trial of insulin produced in plant seeds
Date:12/3/2008

as required by European Union (EU) regulations. Successful completion of this clinical trial in Europe should contribute to the satisfaction of regulatory requirements in Europe and North America. Both the United States and European regulatory authorities have confirmed that SBS-1000 insulin is eligible to receive approval through an abbreviated regulatory path.

About SBS-1000

SBS-1000 is human insulin produced from genetically enhanced safflower. SemBioSys has demonstrated that SBS-1000 insulin is physically, structurally and functionally indistinguishable from pharmaceutical-grade human insulin through analytical testing and pre-clinical sub-chronic toxicology studies in rodents and primates.

About SemBioSys Genetics Inc.

Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology company developing protein-based pharmaceuticals using its proprietary protein production technology. This technology enables the production of therapeutic proteins in plant seeds by genetically enhancing the safflower plant. The Company's lead pharmaceutical candidates are recombinant human insulin, which intends to serve the rapidly expanding global diabetes market, and Apo AI Milano. Apo AI Milano is a variant of Apo AI, the major protein associated with high density lipoprotein (HDL), or "good cholesterol", whose function is to remove excess cholesterol from arteries. In addition to its pharmaceutical products, SemBioSys' subsidiary, Botaneco Specialty Ingredients Inc., is selling oleosome-based all natural products in the global personal care ingredient market. More information is available and can be accessed at www.sembiosys.com.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticip
'/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND
2. SemBioSys announces second quarter 2008 financial and operational results
3. SemBioSys submits IND for safflower-produced insulin to U.S. FDA
4. SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano)
5. SemBioSys to present at the Needham & Company Biotechnology and Medical Technology Conference
6. SemBioSys provides update on shrimp feed additive, Immunosphere(TM)
7. SemBioSys announces first quarter 2008 financial and operational results
8. SemBioSys receives milestone payments from AVAC Ltd.
9. SemBioSys initiates toxicology study for safflower-produced insulin
10. SemBioSys announces 2007 financial and operational results
11. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... May 21, 2015 uBiome, the ... a partnership with PicnicHealth, a healthcare company that ... diagnosed with Inflammatory Bowel Disease (IBD) will receive ... complementary uBiome research kit. Both companies were funded ... , For more information on this partnership ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 W. ... its manufacturing facility in Worms, Germany has received ... independent subsidiary of the International Pharmaceutical Excipient Council ... facilities that produce its SYLOID® FP brand of ... GMP certification, following the Curtis Bay, Maryland (USA) ...
(Date:5/21/2015)... May 21, 2015 As part of ... Center (BDWMC), Sun Health Foundation funded a $3.25 million ... inpatient pharmacy with the most up-to-date features and technology. ... 2. The pharmacy's 45 staff members will begin moving ... space in the coming days. , The current ...
(Date:5/21/2015)... Kingston, Ontario (PRWEB) May 21, 2015 ... entered into an exclusive North American distribution agreement ... microbiology testing system. , With more than 160 ... of products and services for laboratory and production ... choice, operational excellence and differentiated services to enable ...
Breaking Biology Technology:uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 3Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2
... 29 BioMed Realty Trust, Inc.,(NYSE: BMR ), a ... life science industry, today announced financial results for,the third quarter ... total revenues increased 24.6% to $80.8 million from ... -- Completed delivery of the 84,000 square foot build-to-suit laboratory ...
... 29 MannKind,Corporation (Nasdaq: MNKD ) will release ... 2008 at 8:00 a.m. EST., Management of the ... quarter financial results, clinical progress and other Company,developments at ... the,Company will be its Chairman and Chief Executive Officer, ...
... Inc. (Nasdaq: SGMO ) today reported third quarter ... ended September 30, 2008, Sangamo reported a,consolidated net loss ... a,net loss of $4.3 million, or $0.11 per share, ... 2008, the company had cash, cash equivalents and,investments of ...
Cached Biology Technology:BioMed Realty Trust Reports Third Quarter 2008 Financial Results 2BioMed Realty Trust Reports Third Quarter 2008 Financial Results 3BioMed Realty Trust Reports Third Quarter 2008 Financial Results 4BioMed Realty Trust Reports Third Quarter 2008 Financial Results 5BioMed Realty Trust Reports Third Quarter 2008 Financial Results 6BioMed Realty Trust Reports Third Quarter 2008 Financial Results 7BioMed Realty Trust Reports Third Quarter 2008 Financial Results 8BioMed Realty Trust Reports Third Quarter 2008 Financial Results 9BioMed Realty Trust Reports Third Quarter 2008 Financial Results 10BioMed Realty Trust Reports Third Quarter 2008 Financial Results 11BioMed Realty Trust Reports Third Quarter 2008 Financial Results 12BioMed Realty Trust Reports Third Quarter 2008 Financial Results 13MannKind Corporation to Hold Third Quarter Financial Results Conference Call on November 5, 2008 2Sangamo BioSciences Reports Third Quarter 2008 Financial Results 2Sangamo BioSciences Reports Third Quarter 2008 Financial Results 3Sangamo BioSciences Reports Third Quarter 2008 Financial Results 4Sangamo BioSciences Reports Third Quarter 2008 Financial Results 5Sangamo BioSciences Reports Third Quarter 2008 Financial Results 6Sangamo BioSciences Reports Third Quarter 2008 Financial Results 7
(Date:5/19/2015)... YORK , May 19, 2015  Technology is ... both internally and in the cloud. Passwords and their ... use of OTP and standards-based specifications such as those ... the outmoded use of passwords presents for BYOD, COPE, ... a unified biometric identity protocol. In ...
(Date:5/18/2015)... Sweden , May 18, 2015 ... fingerprint sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one ... from June until and including Q3 2015 and the sensors ... . Communicated order values for 2015 hereby amount to ... for Q1 2015 of 140 MSEK and a number of ...
(Date:5/14/2015)... , May 14, 2015  Verificient Technologies, ... verification and online remote proctoring, announced a ... (SaaS) company and creator of the Canvas ... the two companies will benefit from the ... As a fully integrated multifactor ...
Breaking Biology News(10 mins):HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2
... University of Notre Dame biochemist Anthony S. Serianni is ... understanding and treating diabetes. Serianni points out that ... the human body from the natural breakdown of the ... enhanced in diabetic patients because glucose concentrations in the ...
... often carried out in tiny protective shells known as ... carbon dioxide into energy in plant cells and to ... Most of these shells buckle into an icosahedron shape, ... their surroundings. But some shells such as those ...
... brain tumors emerging among raccoons in Northern California and Oregon ... a team of researchers, led by scientists from the University ... Emerging Infectious Diseases , could lead to a better ... humans. Necropsies conducted since March 2010 by scientists at ...
Cached Biology News:Notre Dame research may have important implications for combating diabetes 2New geometries: Researchers create new shapes of artificial microcompartments 2Emerging virus in raccoons may provide cancer clues 2Emerging virus in raccoons may provide cancer clues 3
BD Falcon 850 cm Smooth-surface TufRol Roller Bottle, tissue-culture treated polystyrene, blow-molded one-piece design, with easy on/off non-vented cap, packed in double bag. (20/ca) Packaging: ...
... Flight Mass Analyzer for superior sensitivity, mass accuracy, and resolving power., ... * Precursor ion selection range: 150 - 4000 m/z, * Resolution: ... internal reference, * Dynamic range: 4 orders of magnitude ... ...
... The pYD1 Yeast Display Vector is ... proteins on the surface of Saccharomyces cerevisiae. ... ability to interact with known or putative ... receptor which consists of two domains, Aga1 ...
... Oncostatin M (OSM) is a pleiotropic cytokine ... Kaposis sarcoma cells. OSM inhibits the growth ... simulates fibroblast, smooth muscle and Kaposis sarcoma ... and low density lipoprotein receptor expression on ...
Biology Products: